Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Vanda Pharmaceuticals
- Study ID
- NCT07221578
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Social Anxiety Disorder (SAD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- VQW-765 — DRUGoral capsule
- Placebo — DRUGoral capsule
Study Details
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
Key Dates
- Start date
- Sep 22, 2025
- Status verified
- May 2026
- Primary completion
- Dec 31, 2026
- Completion
- Apr 30, 2027
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: VQW-765
- Placebo Comparator: Placebo
Primary Outcome Measure
Subjective Units of Distress Scale (SUDS) [ Time Frame: 1 day ]
Central Contacts
- Vanda Pharmaceuticals, Inc.202-734-3400
Locations (30)
Find similar trials in Phoenix, AZ
Related Studies
- Stepped Care Treatment for Anxiety ResilienceRecruiting · Andrew Wiese · Houston, Texas
- A Study of NTX-1472 in Social Anxiety DisorderPHASE2 · Recruiting · Newleos Therapeutics, Inc. · Pheonix, Arizona